Literature DB >> 30690619

Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria.

Maaike Boonstra1, Maarten K Ninaber2, Nina Ajmone Marsan3, Tom W J Huizinga1, Hans Ulrich Scherer1, Jeska K de Vries-Bouwstra1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30690619     DOI： 10.1093/rheumatology/kez005

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  3 in total

1.  New risk model is able to identify patients with a low risk of progression in systemic sclerosis.

Authors:  Nina Marijn van Leeuwen; Marc Maurits; Sophie Liem; Jacopo Ciaffi; Nina Ajmone Marsan; Maarten Ninaber; Cornelia Allaart; Henrike Gillet van Dongen; Robbert Goekoop; Tom Huizinga; Rachel Knevel; Jeska De Vries-Bouwstra
Journal:  RMD Open       Date:  2021-05

2.  Disease progression in systemic sclerosis.

Authors:  Nina M van Leeuwen; Sophie I E Liem; Marc P Maurits; Maarten Ninaber; Nina Ajmone Marsan; Cornelia F Allaart; Tom W J Huizinga; Rachel Knevel; Jeska K de Vries-Bouwstra
Journal:  Rheumatology (Oxford)       Date:  2021-03-02       Impact factor: 7.580

3.  Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis.

Authors:  Maaike Boonstra; Jaap A Bakker; Annette Grummels; Maarten K Ninaber; Nina Ajmone Marsan; Corrie M Wortel; Tom W J Huizinga; Suzana Jordan; Anna-Maria Hoffman-Vold; Oliver Distler; René E M Toes; Hans Ulrich Scherer; Jeska K de Vries-Bouwstra
Journal:  Arthritis Rheumatol       Date:  2020-09-29       Impact factor: 10.995
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.